CompletedPhase 3

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

NCT03084939

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

Beijing Hospital

Beijing, China

+17 additional locations

Save this trial

Beijing HospitalBeijing, China
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)Beijing, China
Beijing Cancer HospitalBeijing, China
the First Hospital of Jilin UniversityChangchun, China
Jilin Cancer HospitalChangchun, China
Changzhou First People's HospitalChangzhou, China
West China Hospital, Sichuan UniversityChengdu, China
Fujian Medical University Union HospitalFuzhou, China
The Second Affiliated Hospital of Zhejiang University CollegeHangzhou, China
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer departmentHangzhou, China
Harbin Medical University Cancer HospitalHarbin, China
Jiangsu Province HospitalNanjing, China
Jiangsu Cancer HospitalNanjing, China
Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)Shanghai, China
Fudan University Shanghai Cancer CenterShanghai, China
Liaoning cancer Hospital & InstituteShenyang, China
Tianjin Cancer HospitalTianjin, China
First Affiliated Hospital of Medical College of Xi'an Jiaotong UniversityXi'an, China